>
Bone Biologics logo

BBLG - Bone Biologics Share Price

$7.5 0.0  0.0%

Last Trade - 19/03/21

Sector
Healthcare
Size
Small Cap
Market Cap £163.8m
Enterprise Value £172.1m
Revenue £n/a
Position in Universe 4388th / 6856
Bullish
Bearish
Unlock BBLG Revenue
Momentum
Relative Strength (%)
1m -0.42%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BoneBiologics Corp revenues was not reported. Net lossdecreased 47% to $1.8M. Lower net loss reflects General andadministrative decrease of 64% to $484K (expense), Researchand development decrease of 69% to $341K (expense). BasicEarnings per Share excluding Extraordinary Items increasedfrom -$0.47 to -$0.25.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BBLG Revenue Unlock BBLG Revenue

Net Income

BBLG Net Income Unlock BBLG Revenue

Normalised EPS

BBLG Normalised EPS Unlock BBLG Revenue

PE Ratio Range

BBLG PE Ratio Range Unlock BBLG Revenue

Dividend Yield Range

BBLG Dividend Yield Range Unlock BBLG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BBLG EPS Forecasts Unlock BBLG Revenue
Profile Summary

Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company's platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company's platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated October 18, 2007
Public Since November 27, 2015
No. of Shareholders: 57
No. of Employees: 1
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Pink Sheets on Nasdaq
Shares in Issue 30,682,590
Free Float (0.0%)
Eligible for
× ISAs
SIPPs
BBLG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BBLG
Upcoming Events for BBLG
Frequently Asked Questions for Bone Biologics
What is the Bone Biologics share price?

As of 19/03/21, shares in Bone Biologics are trading at $7.5, giving the company a market capitalisation of £163.8m. This share price information is delayed by 15 minutes.

How has the Bone Biologics share price performed this year?

Shares in Bone Biologics are currently trading at $7.5 and the price has moved by 87.5% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bone Biologics price has moved by 26.23% over the past year.

What are the analyst and broker recommendations for Bone Biologics?

There are no analysts currently covering Bone Biologics.

When will Bone Biologics next release its financial results?

Bone Biologics is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bone Biologics dividend yield?

Bone Biologics does not currently pay a dividend.

Does Bone Biologics pay a dividend?

Bone Biologics does not currently pay a dividend.

When does Bone Biologics next pay dividends?

Bone Biologics does not currently pay a dividend.

How do I buy Bone Biologics shares?

To buy shares in Bone Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bone Biologics?

Shares in Bone Biologics are currently trading at $7.5, giving the company a market capitalisation of £163.8m.

Where are Bone Biologics shares listed? Where are Bone Biologics shares listed?

Here are the trading details for Bone Biologics:

Country of listing: United States
Exchange: PNK
Ticker Symbol: BBLG
What kind of share is Bone Biologics?

Based on an overall assessment of its quality, value and momentum, Bone Biologics is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bone Biologics share price forecast 2021?

We were not able to load any forecast data for Bone Biologics.

How can I tell whether the Bone Biologics share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bone Biologics. Over the past six months, the relative strength of its shares against the market has been 0.118k%. At the current price of $7.5, shares in Bone Biologics are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bone Biologics PE Ratio?

We were not able to find PE ratio data for Bone Biologics.

Who are the key directors of Bone Biologics?

Bone Biologics's management team is headed by:

Deina Walsh - CFO
Bruce Stroever - DRC
John Booth - IND
Stephen La Neve - DRC
Jeffrey Frelick - PRE
Bret Hankey - DRC
Don Hankey - CHM
Who are the major shareholders of Bone Biologics?

Here are the top five shareholders of Bone Biologics based on the size of their shareholding:

Hankey Capital LLC Corporation
Percentage owned: 13.24% (4.06m shares)
Musculoskeletal Transplant Foundation Corporation
Percentage owned: 4.82% (1.48m shares)
Hankey (Don R) Individual Investor
Percentage owned: 1.18% (362k shares)
H & H Funding, L.L.C. Corporation
Percentage owned: 0.26% (79.2k shares)
Hankey (Bret Conrad) Individual Investor
Percentage owned: 0.09% (28.0k shares)
Similar to BBLG
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.